Balyasny Asset Management
QNCX icon

Balyasny Asset Management’s Quince Therapeutics QNCX Stock Holding History

Balyasny Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139
Closed -$93K – 3410
2025
Q4 		$93K Buy
+139
New +$69.9K ﹤0.01% 2965

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Balyasny Asset Management's QNCX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 139 shares — an estimated $93K sold.

Balyasny Asset Management first reported a position in QNCX in Q4 2025 and held it in 1 quarter. The position peaked at $93K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 139 Quince Therapeutics shares in Q1 2026, an estimated $93K.
  • Balyasny Asset Management first reported a position in Quince Therapeutics in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Quince Therapeutics position peaked at $93K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.